<DOC>
	<DOCNO>NCT00736749</DOCNO>
	<brief_summary>This clinical trial keep track collect follow-up information patient currently enrol participate Children 's Oncology Group study . Developing way keep track patient participate Children 's Oncology Group study may allow doctor learn long-term effect cancer treatment help reduce problem relate treatment improve patient quality life .</brief_summary>
	<brief_title>Long-Term Follow-Up Patients Who Have Participated Children 's Oncology Group Studies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To develop mechanism track retain patient enrol Children 's Oncology Group ( COG ) protocols . II . To maintain regular , lifetime contact patient order obtain current identification contact information , self/parent-reported health status . III . To locate patient lost-to-follow-up COG ( Legacy Group ) protocols targeted follow-up Long-Term Follow-Up Center ( LTFC ) . IV . To provide current patient contact information self/parent-reported health status update COG Statistics Data Center ( SDC ) patient 's COG institution . V. To facilitate collection protocol-specific outcome data collaboration COG Late Effects Committee , SDC , member institution . VI . To collect cumulative therapeutic exposure data ( via therapeutic summary complete online treat institution ) patient complete active therapy . OUTLINE : This umbrella protocol long-term follow-up COG institution . Approximately 6 month completion therapy patient receive mail packet introduce Long-Term Follow-Up Center ( LTFC ) contain information relate individualized , protocol-specific follow-up guideline . Patients ask complete patient response form , verify information provide packet , update contact information , complete Health Status Update Form . The Health Status Update Form brief document include question current health status , disease status , cancer therapy receive since last mailing . Patients receive protocol-specific automatic reminder , may respond use postage prepaid envelope , email , 24-hour toll-free telephone number .</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>The patient must enrol frontline COG therapeutic trial treatment primary malignancy near completion recently complete protocol treatment ( within past 180 day ) * ; patient must enrol COG ( Legacy Group ) therapeutic nontherapeutic trial target longterm followup ALTE05N1 Hodgkin lymphoma CCG5942 POG9425 POG9426 COGAHOD0031 Brain tumor CCGA9961 Acute lymphoblastic leukemia POG9404 Rhabdomyosarcoma IRSIII IRSIV Note : For purpose enrollment onto study , completion treatment define date protocol therapy terminate report ( report ) patient 's last `` Reporting Period Worksheet/CRF '' frontline therapeutic protocol ; patient become eligible approach date , remain eligible 180 day follow date protocol therapy terminate ; early termination protocol therapy per decision patient , family and/or investigator NOT preclude enrollment study Note : For purpose eligibility ALTE05N1 , `` early termination protocol therapy '' mean patient finish protocol therapy receive treatment ; patient whose therapy terminate early due toxicity opt endoftherapy randomization ( e.g. , randomization continue experimental agent vs. treatment ) eligible receive therapy ; however , patient remove protocol therapy opts discontinue protocol participation early course treatment ( e.g. , follow Induction ) eligible The patient must reside U.S. date enrollment ALTE05N1 All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>